Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy-Reference-Cited by-同舟云学术

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

Published:2018-07-01 Issue:7 Volume:4 Page:994
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Hernandez Inmaculada¹²,Prasad Vinay³⁴⁵,Gellad Walid F.²⁶

Affiliation:

1. Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania

2. Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania

3. Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland

4. Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland

5. Center for Health Care Ethics, Oregon Health & Science University, Portland

6. Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference6 articles.

1. A comparison of costs between medical and surgical patients in an academic pediatric intensive care unit.;Hsu;WMJ,2015

2. Professional fee ratios for US hospital discharge data;Peterson;Med Care,2015

3. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.;Hettle;Health Technol Assess,2017

4. Novartis. Tisagenlecleucel (CTL019) for the treatment of pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Oncologic Drugs Advisory Committee briefing document. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm566168.pdf. Published July 12, 2017. Accessed September 5, 2017.

5. Novartis. Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL. https://www.novartis.com/news/media-releases/novartis-pivotal-ctl019-6-month-follow-data-show-durable-remission-rates. Published June 23, 2017. Accessed October 10, 2017.

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tuning Lipid Nanoparticles for RNA Delivery to Extrahepatic Organs;Advanced Materials;2024-09-05

2. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand;Blood;2024-08-29

3. Challenges and opportunities for access to Advanced Therapy Medicinal Products in Brazil;Cytotherapy;2024-08

4. Adoptive T cell therapy for ovarian cancer;Gynecologic Oncology;2024-07

5. Artificial Intelligence-Powered Molecular Docking and Steered Molecular Dynamics for Accurate scFv Selection of Anti-CD30 Chimeric Antigen Receptors;International Journal of Molecular Sciences;2024-06-30